Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05919238 · ClinicalTrials.gov registry record · Phase 1
Padeliporfin VTP Treatment for Unresectable Pancreatic Adenocarcinoma
A Phase 1 study of Locally Advanced Unresectable Pancreatic Adenocarcinoma, sponsored by Impact Biotech.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 2
- Study locations
NCT05919238: Recruiting Phase 1 study of Locally Advanced Unresectable Pancreatic Adenocarcinoma, sponsored by Impact Biotech.
NCT05919238 is a Phase 1 study of Locally Advanced Unresectable Pancreatic Adenocarcinoma that is actively recruiting participants, run by Impact Biotech. The registered enrollment target is 30 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05919238, a Phase 1 study of Locally Advanced Unresectable Pancreatic Adenocarcinoma, is actively recruiting participants, sponsored by Impact Biotech.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a prospective, multicenter, non-randomized, open label light dose escalation phase I trial to evaluate the safety and preliminary efficacy of Padeliporfin vascular targeted photodynamic therapy (VTP) applied via endovascular fiber placement within a dilatation catheter, through the target artery(superior mesenteric artery (SMA), celiac artery (CA) or common hepatic artery (CHA)). The investigators will evaluate safety and preliminary efficacy of Padeliporfin VTP administered endovascularly using light dose escalation.
Primary Outcome
Safety of endovascularly applied Padeliporfin VTP ablation will be assessed using the CTCAE version 5.0. All adverse events (AEs) will be coded using the Medical Dictionary for Regulatory Activities (MedDRA) for being included in analyses.
Conditions Studied
Interventions
- COMBINATION_PRODUCT Padeliporfin Vascular Targeted Photodynamic (VTP) therapy
Study Locations (2)
California
- City of Hope - Duarte
- University of California Irvine - Irvine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2024-05-15 |
| Est. Completion | 2026-10-30 |
| Phase | Phase 1 |
What NCT05919238 shows while recruiting
NCT05919238 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% lower).
The record links to 1 condition, with Locally Advanced Unresectable Pancreatic Adenocarcinoma appearing as the primary indexed condition, and to 1 intervention - of which Padeliporfin Vascular Targeted Photodynamic (VTP) therapy is the first listed.
NCT05919238 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05919238 about?
NCT05919238 is a clinical study titled "Padeliporfin VTP Treatment for Unresectable Pancreatic Adenocarcinoma". This is a prospective, multicenter, non-randomized, open label light dose escalation phase I trial to evaluate the safety and preliminary efficacy of Padeliporfin vascular targeted photodynamic therapy (VTP) applied via endovascular fiber placement within a dilatation catheter, through the target ar...
What is the current status of trial NCT05919238?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2024-05-15. Estimated completion is 2026-10-30.
What conditions does trial NCT05919238 study?
This clinical trial studies the following conditions: Locally Advanced Unresectable Pancreatic Adenocarcinoma.
What interventions are being tested in trial NCT05919238?
The interventions under investigation include: Padeliporfin Vascular Targeted Photodynamic (VTP) therapy (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT05919238?
This trial is sponsored by Impact Biotech, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05919238 being conducted?
This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Locally Advanced Unresectable Pancreatic Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05919238's enrollment target sits among peer trials
30 1332nd of 2000 higher than 561 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI